Trial watch: anticancer vaccination with dendritic cells
| Title: | Trial watch: anticancer vaccination with dendritic cells |
|---|---|
| Authors: | Francisca Borges, Raquel S. Laureano, Isaure Vanmeerbeek, Jenny Sprooten, Octavie Demeulenaere, Jannes Govaerts, Lisa Kinget, Saurabh Saraswat, Benoit Beuselinck, Steven De Vleeschouwer, Paul Clement, Frederik De Smet, Rüdiger V. Sorg, Angeliki Datsi, Nathalie Vigneron, Stefan Naulaerts, Abhishek D. Garg |
| Source: | OncoImmunology, Vol 13, Iss 1 (2024) |
| Publisher Information: | Taylor & Francis Group, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Immunologic diseases. Allergy LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | Antigen cross-presentation, clinical trial, DAMPs, dendritic cells, immune checkpoint blockers, T cell priming, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), and utilizing maturation cocktails to ensure their effective activation. These matured DCs are then reinfused to elicit tumor-specific T-cell responses. While this approach has demonstrated the ability to generate potent immune responses, its clinical efficacy has been limited due to the immunosuppressive tumor microenvironment. Recent efforts have focused on enhancing the immunogenicity of DC-based vaccines, particularly through combination therapies with T cell-targeting immunotherapies. This Trial Watch summarizes recent advances in DC-based cancer treatments, including the development of new preclinical and clinical strategies, and discusses the future potential of DC-based vaccines in the evolving landscape of immuno-oncology. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2162402X 2162-402X |
| Relation: | https://doaj.org/toc/2162-402X |
| DOI: | 10.1080/2162402X.2024.2412876 |
| Access URL: | https://doaj.org/article/62ea562a7fa84a7596a062de5d9f27c9 |
| Accession Number: | edsdoj.62ea562a7fa84a7596a062de5d9f27c9 |
| Database: | Directory of Open Access Journals |
| ISSN: | 2162402X |
|---|---|
| DOI: | 10.1080/2162402X.2024.2412876 |
| Published in: | OncoImmunology |
| Language: | English |